Tianjin Pharmaceutical Da Ren Tang Group (600329.SS) Earnings Analysis
Tianjin Pharmaceutical Da Ren Tang Group (600329.SS) has no confirmed upcoming earnings date. Trailing P/E 13.25.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 600329.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 600329.SS. This page updates as the calendar is published.
600329.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-31 | -0.0275 CNY | n/a | n/a | n/a |
| 2025-10-31 | 0.2916 CNY | n/a | n/a | n/a |
| 2024-12-31 | 1.84 CNY | n/a | n/a | n/a |
| 2024-10-30 | 0.1901 CNY | n/a | n/a | n/a |
| 2024-08-14 | 0.3517 CNY | n/a | n/a | n/a |
600329.SS valuation and analyst view
| Trailing P/E | 13.25 |
|---|---|
| Trailing EPS | 2.832 CNY |
| Price / book | 3.84 |
| Dividend yield | 6.24% |
| Market cap | 21.49B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Tianjin Pharmaceutical Da Ren Tang Group (600329.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 600329.SS. This page updates as the calendar is published.
Did 600329.SS beat earnings last quarter?
Consensus estimate data was not available for 600329.SS's 2026-03-31 report.
What is 600329.SS's current P/E ratio and EPS?
600329.SS trades at a trailing P/E of 13.25 on trailing EPS of 2.8315709120714554 CNY.
What do analysts rate 600329.SS?
600329.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.